Cadwalader advised HealthCare Royalty Partners on the deal.HealthCare Royalty Partners closed a revenue financing agreement for up to $125 million for Spero Therapeutics, Inc. (NASDAQ: SPRO), a…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
